Skip to Main Content

Multi-arm Optimization of Stroke Thrombolysis (MOST)

Conditions

Diseases of the Nervous System

Phase III

What is the purpose of this trial?

Brief Summary:

The primary efficacy objective of the MOST trial is to determine if argatroban (100µg/kg bolus followed by 3µg/kg per minute for 12 hours) or eptifibatide (135µg/kg bolus followed by 0.75µg/kg/min infusion for two hours) results in improved 90-day modified Rankin scores (mRS) as compared with placebo in acute ischemic stroke (AIS) patients treated with 0.9mg/kg IV rt-PA within three hours of symptom onset. Patients may also receive endovascular thrombectomy (ET) per usual care. Time of onset is defined as the last time the patient was last known to be well.

  • Trial with
    University of Cincinnati
  • Start Date
    12/04/2019
  • End Date
    02/27/2023
Trial Image

For more information about this study, contact:

Taylor Hoffman

I'm interested in volunteering

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 877.978.8343

  • Last Updated
    12/06/2019
  • Study HIC
    #2000024503